The multiple myeloma armamentarium is large and getting larger. That makes treatment choices complex and the cost of ...

During a live event, Jack Khouri, MD, discussed options for patients with multiple myeloma after relapse and choices to ...

Sarclisa was added to the National Comprehensive Cancer Network (NCCN) guidelines for non-transplant multiple myeloma candidates as a category 1 (preferred) option alongside VRd and Darzalex plus ...

The treatment landscape for multiple myeloma has shifted since European ... reviewed the treatment landscape at the National Comprehensive Cancer Network (NCCN) 2023 Annual Conference.

PGV001, a personalized cancer vaccine, induced immune responses across various cancer types like breast and urothelial cancer, as well as multiple myeloma. PGV001, a personalized multi-peptide ...